The ratios of PTEN alterations in the “MSI-H” group were 85.2% (52/61) in endometrial, 69.2% (9/13) in cervical, and 57.9% (11/19) in ovarian cancers, whereas the ratios of PTEN alterations in the “MSS with TMB-L” group were 28.2% (127/451) in endometrial, 7.5% (49/650) in cervical, and 6.3% (92/1449) in ovarian cancers. This evidence concerns the gene PTEN and ovarian carcinoma.